Advanced search
Publication Cover
Neuro-Ophthalmology Volume 43, 2019 - Issue 1
Submit an article Journal homepage
177
Views
24
CrossRef citations to date
0
Altmetric
Original Articles

Ganglion Cell Complex Analysis as a Potential Indicator of Early Neuronal Loss in Idiopathic Intracranial Hypertension

Geetha AthappillyThe New England Eye Center, Tufts Medical Center, Boston, Massachusetts, USA;Department of Ophthalmology, Lahey Clinic, Burlington, Massachusetts, USACorrespondence[email protected]
View further author information
,
Ignacio García-BasterraHospital Costa del Sol, Marbella, SpainView further author information
,
Flavia Machado-MillerThe New England Eye Center, Tufts Medical Center, Boston, Massachusetts, USAView further author information
,
Thomas R. HedgesThe New England Eye Center, Tufts Medical Center, Boston, Massachusetts, USAView further author information
,
Carlos Mendoza-SantiestebanBascom Palmer Eye Institute, University of Miami, Miami, Florida, USAView further author information
&
Laurel VuongThe New England Eye Center, Tufts Medical Center, Boston, Massachusetts, USAView further author information
Pages 10-17 | Received 04 Jul 2017, Accepted 10 May 2018, Published online: 19 Jun 2018

References

  • Kilgore KP, Lee MS, Mokri B, et al. Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity. Ophthalmology. 2017;124(5):697–700. doi:10.1016/j.ophtha.2017.01.006.
  • Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from 5 to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol. 1982;39:461–474. doi:10.1001/archneur.1982.00510200003001.
  • Lee IJ, Maccheron LJ, Kwan AS. Intravitreal bevacizumab in the treatment of peripapillary choroidal neovascular membrane secondary to idiopathic intracranial hypertension. J Neuroophthalmol. 2013 Jun;33(2):155–157. doi:10.1097/WNO.0b013e31827c6b49.
  • Chen JJ, Thurtell MJ, Longmuir RA, et al. Causes and prognosis of visual acuity at the time of initial presentation in idiopathic intracranial hypertension. Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3850–3859. doi:10.1167/iovs.15-16450.
  • Cello KE, Keltner JL, Johnson CA, Wall M. Factors affecting visual field outcomes in the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol. 2016;36(1):6–12. doi:10.1097/WNO.0000000000000327.
  • Wall M, Johnson CA, Cello KE, Zamba KD, McDermott MP, Keltner JL. Visual field outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci. 2016;57(3):805–808. doi:10.1167/iovs.15-18626.
  • Ney JJ, Volpe NJ, Liu GT, Balcer LJ, Moster ML, Galetta SL. Functional visual loss in idiopathic intracranial hypertension. Ophthalmology. 2009 Sep;116(9):1808–1813.e1. doi:10.1016/j.ophtha.2009.03.056.
  • Kutzko KE. Brito CF and Wall M. Effect of instructions on conventional automated perimetry. Invest Ophthalmol Vis Sci. 2000;41:2006–2013.
  • Optical Coherence Tomography Substudy Committee, NORDIC Idiopathic Intracranial Hypertension Study Group. Papilledema outcomes from the optical coherence tomography substudy of the idiopathic intracranial hypertension treatment trial. Ophthalmology. 2015;122(9):1939–1945. doi:10.1016/j.ophtha.2015.06.003.
  • Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2002;59(10):1492–1495. doi:10.1212/01.WNL.0000029570.69134.1B.
  • Zalta AH. Lens rim artifact in automated threshold perimetry. Ophthalmology. 1989;96(9):1302–1311. doi:10.1016/S0161-6420(89)32722-9.
  • Lindenmuth KA, Skuta GL, Rabbani R, Musch DC. Effects of pupiliary constriction on automated perimetry in normal eyes. Ophthalmology. 1989;96(9):1298–1301. doi:10.1016/S0161-6420(89)32723-0.
  • Bianchi S, Ciasca P, Curone M, et al. Quantitative analysis of optic nerve damage in idiopathic intracranial hypertension (IIH) at diagnosis. Neurol Sci. 2013;34(s1):143–145. doi:10.1007/s10072-013-1373-1.
  • Rebolleda G, Muñoz-Negrete FJ. Follow-up of mild papilledema in idiopathic intracranial hypertension with optical coherence tomography. Invest Ophthalmol Vis Sci. 2009;50(11):5197–5200. doi:10.1167/iovs.08-2528.
  • Skau M, Sander B, Milea D, Jensen R. Disease activity in idiopathic intracranial hypertension: a 3-month follow-up study. J Neurol. 2010;258(2):277–283. doi:10.1007/s00415-010-5750-x.
  • Kaufhold F, Kadas EM, Schmidt C, et al. Optic nerve head quantification in idiopathic intracranial hypertension by spectral domain OCT. PLoS ONE. 2012;7(5):e36965. doi:10.1371/journal.pone.0036965.
  • OCT Sub-Study Committee for the NORDIC Idiopathic Intracranial Hypertension Study Group. Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: quality control, comparisons, and variability. Invest Ophthalmol Vis Sci. 2014;55(12):8180–8188. doi:10.1167/iovs.14-14960.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.